|
| | Case 1 | Case 2 |
|
| Age (years)/gender | 77/male | 47/male |
|
Possible/probable exposure
Date/timing of exposure | Cape Verde
From 1944 to 1965 | Guinea-Bissau
From several years to months before |
|
| Risk factors for infection and HIS/DS (3, 7, 8) |
| Alcoholism | No | No |
| HIV-infection | No | No |
| HTLV-1 infection | No | No |
| Hematologic malignancy | No | No |
| Solid organ transplant | No | No |
| Immunosuppressive therapy | Yes | Yes |
| Type | Corticosteroid (dexamethasone) | Corticosteroid (dexamethasone) |
| Cumulative dose equivalence (prednisone) until HIS/DS | 1426 mg | 3067 mg |
| Time from beginning immunosuppression to HIS/DS | 32 days | 37 days |
|
| Other comorbidities | Hypertension
Dyslipidaemia | Colon adenocarcinoma in remission
Chronic kidney disease
Previous hepatitis B |
|
| Confirmed organ/system involvement during DS | Gastrointestinal
Pulmonary
Urinary
Central nervous system | Gastrointestinal
Pulmonary
Urinary |
|
| Strongyloidiasis therapy given | Ivermectin 200 μg/kg id (oral, NGT)
Albendazole 400 mg bid (oral, NGT) | Ivermectin 200 μg/kg id (oral, NGT) 10 days
Ivermectin 200 μg/kg id (subcutaneous) 5 days
Albendazole 400 mg bid (oral, NGT) 15 days |
|
| Complications | (i) Bacteraemia due to K. pneumoniae
(ii) Ventilator-associated pneumonia due to KPC-producing K. pneumoniae
(iii) Meningitis to E. faecium | (i) CMV reactivation with possible colitis
(ii) Pulmonary aspergillosis
(iii) Bacteraemia due to K. pneumoniae
(iv) Bloodstream infection due to C. albicans
(v) HSV-1/VZV oral mucositis
(vi) HBV reactivation |
|
| Outcome and time to outcome (after diagnosis) | Cure of strongyloidiasis in 4 weeks
Death after 61 days (due to hospital-acquired SARS-CoV-2 pneumonia) | No cure for strongyloidiasis
Death after 15 days |
|
